Antioxidant therapy in the treatment of patients with chronic cerebral ischemia

Background. Pathogenetic therapy of chronic cerebral ischemia (CCI) should be aimed at optimizing cerebral blood flow and creating neurometabolic brain protection against ischemia and hypoxia. Objective. Evaluation of the efficacy and safety of therapy with the antioxidant ethylmethylhydroxypyridine succinate at a dose of 250 mg 3 times a day for 60 days in patients with CCI against the background of arterial hypertension and atherosclerosis. Methods. The study included 40 patients aged 45-75 years with a verified diagnosis of CCI, randomized into 2 groups: 1 - the main group receiving treatment with ethylmethylhydroxypyridine succinate 250 mg, 2 - the control group receiving treatment as part of the correction of risk factors in accordance with generally accepted standards for the management of arterial hypertension and atherosclerosis. Effectiveness of therapy was assessed using the CGI, MoCa, MFI-20, and Tinnetti scales. Results. Against the background of treatment with ethylmethylhydroxypyridine succinate 250 mg, the main group showed a significant decrease in the severity of asthenia symptoms according to MFI-20, an increase in mental capacity and task performance speed according to MoSa, and an increase in motor activity according to the Tinneti scale. The drug proved to be safe when used at a dose of 750 mg/day in the treatment of CCI for 2 months. Conclusion. The results of using the ethylmethylhydroxypyridine succinate indicate its efficacy and safety in the treatment of the main neurological and neuropsychiatric CCI symptoms. Ethylmethylhydroxypyridine succinate at a dose of 250 mg 3 times a day can be recommended for the treatment of CCI in patients with arterial hypertension and atherosclerosis.

chronic cerebral ischemia, asthenia, cognitive deficiency, anxiety, antioxidant therapy, ethylmethylhydroxypyridine succinate